Payment for services is made exclusively to the company's account. For your convenience, we have launched Kaspi RED 😎

Home / Convention / Resolution / Concept / On the Concept for the Development of the Common Market for Medicinal Products within the Eurasian Economic Union

On the Concept for the Development of the Common Market for Medicinal Products within the Eurasian Economic Union

АMANAT партиясы және Заң және Құқық адвокаттық кеңсесінің серіктестігі аясында елге тегін заң көмегі көрсетілді

On the Concept for the Development of the Common Market for Medicinal Products within the Eurasian Economic Union

Order No. 9 of the Eurasian Intergovernmental Council dated August 15, 2025.

For the purpose of implementing paragraph 4.10.1 of the Strategic Directions for the Development of Eurasian Economic Integration until 2025, approved by Decision No. 12 of the Supreme Eurasian Economic Council dated December 11, 2020:

1. The Concept for the Development of the Common Market for Medicinal Products within the Eurasian Economic Union shall be approved.

The Eurasian Economic Commission shall publish the aforementioned Concept on the official website of the Eurasian Economic Union.

2. The Governments of the Member States of the Eurasian Economic Union and the authorized bodies of the Member States of the Eurasian Economic Union in the field of medicinal product circulation shall be guided by the Concept for the Development of the Common Market for Medicinal Products within the Eurasian Economic Union in order to ensure the development of the common market for medicinal products.

3. This Order shall enter into force on the date of its publication on the official website of the Eurasian Economic Union.

Members of the Eurasian Intergovernmental Council:

On behalf of the Republic of ArmeniaOn behalf of the Republic of BelarusOn behalf of the Republic of KazakhstanOn behalf of the Kyrgyz RepublicOn behalf of the Russian Federation
 APPROVED by Order No. 9 of the Eurasian Intergovernmental Council dated August 15, 2025

CONCEPT for the Development of the Common Market for Medicinal Products within the Eurasian Economic Union

I. General Provisions

This Concept for the Development of the Common Market for Medicinal Products within the Eurasian Economic Union (hereinafter referred to, respectively, as the Concept, the common market for medicinal products, the Union or the EAEU) has been developed for the purpose of implementing Measure 4.10.1 of the Strategic Directions for the Development of Eurasian Economic Integration until 2025, approved by Decision No. 12 of the Supreme Eurasian Economic Council dated December 11, 2020.

The formation of the common market for medicinal products is carried out in accordance with the principles specified in Article 30 of the Treaty on the Eurasian Economic Union (hereinafter referred to as the Treaty), the Treaty on the Eurasian Economic Union, the Agreement on Common Principles and Rules for the Circulation of Medicinal Products within the Eurasian Economic Union dated December 23, 2014 (hereinafter referred to as the Agreement), and the national legislation of the EAEU Member States.

EAEU law provides for the development of medicinal products, preclinical and clinical studies, manufacturing, registration and expert assessment of medicinal products, wholesale distribution, pharmacovigilance, pharmaceutical inspections, and pharmacopoeial standardization.

Acts have been adopted and tasks have been accomplished that have made it possible to ensure the sustainable functioning of the common market for medicinal products.

In 2015–2023, acts were adopted and tasks were accomplished in this area, which made it possible to establish the legal framework for the creation and sustainable functioning of the EAEU common market for medicinal products, including during the COVID-19 pandemic.

As a result of the joint work of the Commission and the authorized bodies of the Member States, aimed at ensuring the optimal introduction of safe, effective and high-quality medicinal products to the market and ensuring their availability to the population and healthcare institutions of the EAEU:

- unified guidelines for the development, preclinical studies and clinical trials of all major groups of medicinal products were established on the basis of the approaches of the World Health Organization (WHO), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and the European Medicines Agency (EMA);

- an integrated system of good pharmaceutical practices of the EAEU was established and implemented, harmonized with the practices of the WHO, ICH, the Organisation for Economic Co-operation and Development (OECD), and the European Union (EU), ensuring uniform regulation of the main stages of the life cycle of medicinal products;

- unified rules for the registration and expert assessment of medicinal products, harmonized with EU rules, were introduced, and a unified international standard for the registration dossier was adopted (at the same time, the EAEU rules establish a number of accelerated and simplified registration procedures for several groups of medicinal products and in special cases);

- the sustainable functioning of the pharmaceutical inspection system for domestic and foreign pharmaceutical manufacturers' production sites to verify compliance with the EAEU Good Manufacturing Practice Rules (Union GMP) was ensured, including the introduction of remote inspection practices and the assessment of the quality of medicinal products in emergency situations;

- in the field of quality control and assurance of pharmacopoeial quality of medicinal products, the Eurasian Economic Union Pharmacopoeia (hereinafter referred to as the Union Pharmacopoeia), unified for all Member States, was developed and put into effect on the basis of national and major global pharmacopoeias;

- in order to ensure information exchange between authorized bodies, the Unified EAEU Information System was launched in 2019, making it possible to maintain a unified register of registered medicinal products, monitor the safety of their circulation, and provide timely information about bans on the circulation of pharmaceutical products and their withdrawal from the market;

- mechanisms were established and put into effect for the mutual recognition by authorized bodies of the results of preclinical studies and clinical trials, expert assessments during registration, pharmaceutical inspections for compliance with Union GMP, and pharmacopoeial quality control of medicinal products;

- ongoing work is being carried out to introduce additions and amendments to the adopted acts, taking into account their application in practice, as well as recommendations, in order to ensure the timely updating and harmonization of EAEU law with international approaches to the regulation of the pharmaceutical industry.

Work is continuing on the preparation and publication of Parts III and IV of Volume 1, as well as Volume 2 of the Union Pharmacopoeia, which will make it possible to ensure, in the long term, unified approaches to quality control of medicinal products released for circulation on the EAEU market and mutual recognition of the results of medicinal product quality assessments.

As a result of the joint work of the Commission and the EAEU Member States, a legal framework has been established for the optimal introduction of safe, effective and high-quality medicinal products to the markets of the EAEU Member States, taking into account the best international legal practices.

This Concept is aimed at the further sustainable development of the common market for medicinal products within the EAEU, taking into account:

the practice of applying the adopted EAEU acts by authorized bodies (expert organizations) in the field of medicinal product circulation, pharmaceutical manufacturers and other interested participants in the common market for medicinal products;

the current state of the common market for medicinal products.

The terms used in this Concept shall have the meanings defined in the Treaty, the Agreement and the acts forming part of EAEU law.

II. Brief Overview of the Current State of the Common Market for Medicinal Products

Article 100 of the Treaty establishes that the common market began operating on January 1, 2016. However, 2019 should be considered the actual date on which the common market for medicinal products began functioning, as this was the year when registration of medicinal products under EAEU rules commenced and the common processes ensuring the necessary information exchange between authorized bodies in the areas of registration, expert assessment and inspection for compliance with Union GMP rules were implemented within the integrated EAEU information system.

Since January 1, 2021, in the Russian Federation, and since July 1, 2021, in the other EAEU Member States, new medicinal products may be registered only under EAEU rules. As of January 1, 2024, 4,468 medicinal products had been registered under EAEU rules, and 13,721 registration applications had been submitted. At the same time, the Russian Federation is the country given priority for registration, accounting for 87.3% (2,189 applications) of all medicinal product registration applications in 2021 and 87.1% (11,957 applications) in 2023. This is due to the fact that the Russian Federation has the largest pharmaceutical market capacity among the other EAEU Member States. The number of medicinal products that have obtained registration certificates or have been submitted for registration on the common market of several states (as recognition states) is insignificant and amounted to 276 names as of January 1, 2024.

This situation could potentially lead to the predominance of medicinal products circulating only in EAEU Member States with large pharmaceutical market capacities (the Russian Federation). As a result, there may be a risk of a certain imbalance in the medicinal products market in terms of ensuring the availability of medicinal products in any of the EAEU Member States.

Registration certificates for medicinal products issued under national rules shall remain valid until 2026. In order to ensure the further circulation of these medicinal products within the customs territory of the EAEU, their registration dossiers must undergo the procedure of bringing them into compliance with EAEU acts and be included in the Unified Register of Registered Medicinal Products of the EAEU.

From January 1, 2026, medicinal products circulating in the EAEU Member States must have only EAEU registration certificates, with the exception of 2 groups of medicinal products intended for use under the following conditions:

military operations, for the prevention and treatment of diseases and injuries resulting from exposure to chemical, biological and radiation factors, developed on the instructions of state authorities of the EAEU Member States authorized in the field of security and defense;

the threat of occurrence or occurrence of emergency situations, for the prevention and treatment of diseases and injuries posing a danger to others, resulting from exposure to chemical, biological and radiation factors.

The circulation of the above two groups of medicinal products shall be carried out in accordance with the national legislation of the EAEU Member States.

Registration of medicinal products under EAEU rules is permitted only on the condition that their manufacture complies with EAEU GMP requirements. In 2019, the process of pharmaceutical inspection of medicinal product manufacturers for compliance with EAEU GMP requirements began. Currently, the EAEU GMP inspection system has been implemented in practice in each of the EAEU Member States.

The system of good practices (GxP) introduced into EAEU law includes 6 of the 11 good practices applied in international practice. In addition to Good Manufacturing Practice (GMP), these are: Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Good Agricultural and Collection Practice for medicinal plant raw materials (GACP), Good Distribution Practice (GDP), and Good Pharmacovigilance Practice (GVP).

One of the important components of the common market is ensuring the application of uniform requirements for the quality of medicinal products in circulation.

Pharmacopoeial standardization of the quality of medicinal products within the EAEU is carried out through the preparation, publication and regular updating of the Union Pharmacopoeia, which is a key element in the system for regulating the circulation of medicinal products on the common market. More than 1,250 general pharmacopoeial monographs have been prepared and approved, comprising the first and second editions of Volume I of the Union Pharmacopoeia and covering the most common types of pharmacopoeial analysis, requirements for instruments and equipment, reagents and volumetric solutions, and requirements for dosage forms.

The Union Pharmacopoeia has the status of a regional pharmacopoeia of the EAEU and is included in the Index of World Pharmacopoeias maintained by the World Health Organization (WHO).

III. Purpose and Objectives of the Concept

The purpose of this Concept is to ensure the sustainable functioning of the EAEU common market for medicinal products, based on uniform principles of mandatory requirements for the safety, efficacy and quality of medicinal products circulating on the EAEU market.

To achieve this objective, the following tasks must be implemented:

1. Compliance with the common principles and rules governing the circulation of medicinal products, ensuring the safety, efficacy and quality of medicinal products circulating on the common market and used for the treatment, prevention and diagnosis of diseases among the population of the EAEU Member States.

2. Ensure the uniformity of the principles and rules for the expert assessment of the safety, efficacy and quality of medicinal products established by acts of the EAEU bodies at individual stages of medicinal product circulation in accordance with the Agreement: during development, preclinical and clinical studies, industrial manufacturing and registration of medicinal products, their distribution, as well as pharmacovigilance and inspection of the stages of medicinal product circulation.

3. Ensure the continuity of the development of pharmacopoeial monographs of the Union Pharmacopoeia, as well as the creation and maintenance of a bank of pharmacopoeial reference standards in the EAEU Member States.

4. Further development and harmonization of the regulation of medicinal product circulation on the common market of the Union in accordance with the Agreement on Common Principles and Rules for the Regulation of the Circulation of Medicinal Products within the Union.

IV. Main Areas for the Development of the Common Market for Medicinal Products, Mechanisms for Achieving the Goal and Implementing the Objectives of the Concept

1. Improvement and Optimization of Registration Procedures and Regulation of Medicinal Product Circulation on the EAEU Common Market

Improvement of acts in the field of medicinal product circulation through the preparation of EAEU documents detailing the requirements for the pharmaceutical development of medicinal products and the application of good pharmaceutical practices at all stages of medicinal product circulation (GLP, GCP, GMP, GDP, GVP), as well as the development of an act on Good Regulatory Practice based on the recommendations of the World Health Organization, for the purpose of recognizing certificates of compliance with GMP requirements (and other regulatory practices) outside the EAEU.

Ensuring continuity of expert assessments of the safety, efficacy and quality of medicinal products between different EAEU Member States during their registration and the transfer (relocation) of registration dossiers between EAEU Member States.

Continuation of work on the preparation of recommendations for the implementation of paragraphs 4 and 5 of Article 30 of the Treaty and subparagraph "d" of paragraph 2 of Article 4 and Article 13 of the Agreement, with regard to harmonizing the processes of developing and applying identical or comparable research and control methods when assessing the quality, efficacy and safety of medicinal products, as well as bringing closer the legislation of the EAEU Member States in the field of control (supervision) of medicinal product circulation when exercising state control (supervision) over the circulation of medicinal products in accordance with the procedure established by the legislation of the Member States.

Ensuring the continuity and acceleration of the development of harmonized general and individual pharmacopoeial monographs for pharmaceutical substances, excipients, substances of natural origin (plant and animal), and medicinal products for inclusion in the Union Pharmacopoeia.

2. Improving the Efficiency of Information Systems in the Field of Medicinal Product Circulation

The use in the EAEU of the international electronic format for submitting a registration dossier for a medicinal product (the so-called eCTD format), its transfer and movement through the resources of the integrated EAEU information system require the implementation of measures aimed at further expanding the use, improving and optimizing information exchange in the registration and circulation of medicinal products.

Among other things, these measures will contribute to expanding access for:

- experts, within the framework of the implementation of Common Process 26, "Formation, Maintenance and Use of the Unified Register of Registered Medicinal Products of the Eurasian Economic Union"¹, to the Union's medicinal products register and the closed part of the registration dossier materials (packaging layouts, regulatory document on the quality of the medicinal product);

- authorized bodies of the Member States of the Union to Common Processes 34.2, "Exchange of Information on the Results of Inspections of Production Sites of Medicinal Product Manufacturers for Compliance with the Requirements of the Good Manufacturing Practice Rules of the Eurasian Economic Union" (hereinafter referred to as CP34.2), 31, "Formation, Maintenance and Use of the Unified Register of Pharmaceutical Inspectors of the Eurasian Economic Union" (hereinafter referred to as CP31), and 29, "Formation, Maintenance and Use of a Unified Information Database on Identified Adverse Reactions (Effects) to Medicinal Products, Including Reports on the Ineffectiveness of Medicinal Products", for the purpose of inspecting pharmaceutical manufacturing facilities, clinical and preclinical research centers, as well as pharmacovigilance;

- pharmaceutical businesses to CP34.2 and CP31 for the purpose of planning pharmaceutical inspections and exchanging data within the framework of pharmacovigilance.

¹ The List of Common Processes was approved by Decision No. 29 of the Board of the Eurasian Economic Commission dated April 14, 2015.

3. Development of Infrastructure and Competencies in the EAEU Member States in the Field of Medicinal Product Circulation

Establishment of a network of authorized laboratories in each EAEU Member State engaged in the development of pharmacopoeial monographs of the Union Pharmacopoeia, which will perform experimental work related to the verification and validation of methods (using pharmacopoeial reference standards) during the preparation of pharmacopoeial monographs of the Union Pharmacopoeia.

Organization of a system for the creation, maintenance and distribution of reference standards of the Union Pharmacopoeia.

Creation and maintenance of a unified register of authorized laboratories in each Member State that carry out quality control of medicinal products.

Organization and conduct of joint interlaboratory comparative testing on a regular basis.

4. Cooperation between EAEU Member States in the Field of Pharmaceutical Product Manufacturing

Continuation of cooperation between manufacturers of the EAEU Member States and the authorized bodies of the EAEU Member States in the field of industrial manufacturing and industrial cooperation within the framework of bilateral and multilateral agreements, in accordance with Article 92 of the Treaty and the Protocol on Industrial Cooperation (Annex No. 27 to the Treaty), as well as the main areas of industrial cooperation aimed at accelerating and increasing the sustainability of industrial development, enhancing the competitiveness of the industrial complexes of the EAEU Member States, implementing effective cooperation aimed at increasing innovation activity, and eliminating barriers in the industrial sector.

5. Development of Regulation of Medicinal Product Circulation Based on the Application of International Experience

The development of regulation of medicinal product circulation in accordance with EAEU law and taking into account international experience will make it possible to introduce advanced international practices into EAEU law.

Expanding cooperation between the Union Pharmacopoeia and the pharmacopoeias of third countries in accordance with the Concept for the Harmonization of the Pharmacopoeias of the EAEU Member States and based on the use of international experience in harmonizing national pharmacopoeial requirements in accordance with paragraph 2 of Article 5 of the Agreement will make it possible to ensure the harmonization of requirements and recognition of quality control results within the framework of specifications for pharmaceutical manufacturers of the EAEU Member States when registering medicinal products in third countries.

The development of interaction between the authorized bodies of the EAEU Member States and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), as well as with the WHO pharmaceutical programme within the framework of the International Conference of Drug Regulatory Authorities (ICDRA), will contribute to the recognition by EAEU partners and third countries of the processes of pharmaceutical development, study, assessment of the safety, efficacy and quality of medicinal products manufactured in the EAEU, as well as to the improvement of the procedure for conducting and recognizing the results of pharmaceutical inspections carried out by the pharmaceutical inspectorates of the EAEU Member States in accordance with paragraph 7 of Article 7 and paragraph 3 of Article 10 of the Agreement.

Work will continue on interaction between the authorized bodies of the Member States of the Union and national and international organizations.

Constitution Law Code Regulatory Act Decree Order Decision Resolution Lawyer Almaty Lawyer Legal Services Legal Consultation Civil Criminal Administrative Cases and Disputes Defense Arbitration Legal Company Kazakhstan Law Office Court Cases Declaration Decree Order Resolution Decision Report Conclusion Application Conclusion Convention Contract Memorandum Methodology Standards Note Rules Programme Charter Statute Article Commentary Resolution Regulation Protocol Draft Programme Rules Messages